Viral Infections
RSSArticles
-
COVID-19 Vaccine, 2023-2024 Formula (Comirnaty, Spikevax)
The newest vaccines target XBB.1.5, which is no longer the dominant circulating variant, but they offer protection against XBB.1.16 and more distant variants (e.g., EG.5.1, FL.1.1.1, and BA.2.86).
-
Comparing Sequelae After Hospitalization with COVID-19, Influenza, or Sepsis
The incidence of most selected new-onset medical conditions did not significantly differ among those who had been hospitalized with COVID-19, influenza, or sepsis.
-
Nirsevimab-alip Injection (Beyfortus)
Nirsevimab can be prescribed to prevent respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants born during or entering their first RSV season.
-
U.S. Long COVID Strategy Takes Flight
HHS opens Office of Long COVID Research and Practice, NIH begins enrollment for key clinical trials.
-
Know HCV Status to Take Effective New Medicines
The prevalence of hepatitis C virus infection is significantly higher in healthcare workers than in the general population. Healthcare workers could access effective medications with few side effects by testing for the virus and pursuing treatment. However, high costs and insurance barriers hinder these efforts.
-
Biden, Congress Transition to New Era of Pandemic Prevention
The White House Office of Pandemic Preparedness and Response Policy will take over the duties of the current COVID-19 and Mpox teams in August.
-
Post-Exposure Rabies Prophylaxis — Shorter, Simpler, and Less Costly
After bites by animals potentially infected with rabies, three-visit (over one week) intradermal rabies vaccination was compared to standard four-visit (over two weeks) intramuscular rabies vaccination. Both vaccine regimens prompted similarly protective neutralizing antibody and T-cell responses. While still off-label, the shorter, simpler regimen could protect patients at lower cost than the current standard regimen.
-
Long-Term Successful Virological Suppression with Dolutegravir Monotherapy in the EARL-SIMPLIFIED Trial
Dolutegravir monotherapy was demonstrated to be non-inferior as compared with combination antiretroviral therapy in EARLY-SIMPLIFIED, a randomized, controlled trial with long-term follow-up that included a highly selected group of people with HIV-1 infection.
-
A Comparison of Sequelae After Hospitalization with COVID-19, Influenza, or Sepsis
The incidence of most selected new-onset medical conditions did not significantly differ among those who had been hospitalized with COVID-19, influenza, or sepsis.
-
APIC 2023 Keynote: IPs Must Reclaim Their Power
The 2023 APIC keynote speaker called for infection preventionists to reclaim their narrative, to tell people what they do in no uncertain terms, and to empower others to do likewise.